Liliane Michalik

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


93 publications

2024 | 2022 | 2021 | 2018 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1995 | 1993 | 1992 | 1991 |
 
Closing the scissor-shaped curve: Strategies to promote gender equality in academia.
Joyce J.A., Masina S., Michalik L., Pot C., Sempoux C., Amati F., 2024/03/14. Cell, 187 (6) pp. 1335-1342. Peer-reviewed.
 
Author Correction: EMPReSS: standardized phenotype screens for functional annotation of the mouse genome
Janier Marc, Almadjub Mohammed, Beuf Olivier, Billotey Claire, Bolbos Radu, Canaple Laurence, Chereul Emmanuel, Grenier Denis, Hiba Bassem, Odet Christophe et al., 2022/03. Nature Genetics, 54 (3) pp. 358-360.
PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions.
Ercolano G., Gomez-Cadena A., Dumauthioz N., Vanoni G., Kreutzfeldt M., Wyss T., Michalik L., Loyon R., Ianaro A., Ho P.C. et al., 2021/05/05. Nature communications, 12 (1) p. 2538. Peer-reviewed.
Low expression of the PPARγ-regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases.
Meylan P., Pich C., Winkler C., Ginster S., Mury L., Sgandurra M., Dreos R., Frederick D.T., Hammond M., Boland G.M. et al., 2021/04/12. Scientific reports, 11 (1) p. 7847. Peer-reviewed.
The Janus face of rosiglitazone.
Pich C., Michalik L., 2018/12/28. Oncotarget, 9 (102) pp. 37614-37615. Peer-reviewed.
 
Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth.
Pich C., Meylan P., Mastelic-Gavillet B., Nguyen T.N., Loyon R., Trang B.K., Moser H., Moret C., Goepfert C., Hafner J. et al., 2018/11/15. Cancer research, 78 (22) pp. 6447-6461. Peer-reviewed.
 
Delayed Hair Follicle Morphogenesis and Hair Follicle Dystrophy in a Lipoatrophy Mouse Model of Pparg Total Deletion.
Sardella C., Winkler C., Quignodon L., Hardman J.A., Toffoli B., Giordano Attianese GMP, Hundt J.E., Michalik L., Vinson C.R., Paus R. et al., 2018/03. The Journal of investigative dermatology, 138 (3) pp. 500-510. Peer-reviewed.
Identification of a novel PPARβ/δ/miR-21-3p axis in UV-induced skin inflammation.
Degueurce G., D'Errico I., Pich C., Ibberson M., Schütz F., Montagner A., Sgandurra M., Mury L., Jafari P., Boda A. et al., 2016. EMBO Molecular Medicine, 8 (8) pp. 919-936. Peer-reviewed.
 
Endothelial, but not smooth muscle, peroxisome proliferator-activated receptor β/δ regulates vascular permeability and anaphylaxis.
Wawrzyniak M., Pich C., Gross B., Schütz F., Fleury S., Quemener S., Sgandurra M., Bouchaert E., Moret C., Mury L. et al., 2015. Journal of Allergy and Clinical Immunology, 135 (6) pp. 1625-1635.e5. Peer-reviewed.
 
PPARβ/δ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells.
Palomer X., Capdevila-Busquets E., Botteri G., Salvadó L., Barroso E., Davidson M.M., Michalik L., Wahli W., Vázquez-Carrera M., 2014. International Journal of Cardiology, 174 (1) pp. 110-118.
 
PPARβ/δ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism.
Salvadó L., Barroso E., Gómez-Foix A.M., Palomer X., Michalik L., Wahli W., Vázquez-Carrera M., 2014. Diabetologia, 57 (10) pp. 2126-2135. Peer-reviewed.
Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer.
Montagner A., Delgado M.B., Tallichet-Blanc C., Chan J.S., Sng M.K., Mottaz H., Degueurce G., Lippi Y., Moret C., Baruchet M. et al., 2014. EMBO Molecular Medicine, 6 (1) pp. 80-98.
 
Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice.
Barroso E., del Valle J., Porquet D., Vieira Santos A.M., Salvadó L., Rodríguez-Rodríguez R., Gutiérrez P., Anglada-Huguet M., Alberch J., Camins A. et al., 2013. Biochimica et Biophysica Acta. Molecular Basis of Disease, 1832 (8) pp. 1241-1248. Peer-reviewed.
 
PPARs at the crossroads of lipid signaling and inflammation.
Wahli W., Michalik L., 2012. Trends in Endocrinology and Metabolism, 23 (7) pp. 351-363.
 
The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
Serrano-Marco L., Barroso E., El Kochairi I., Palomer X., Michalik L., Wahli W., Vázquez-Carrera M., 2012. Diabetologia, 55 (3) pp. 743-751.
Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.
Serrano-Marco L., Rodríguez-Calvo R., El Kochairi I., Palomer X., Michalik L., Wahli W., Vázquez-Carrera M., 2011. Diabetes, 60 (7) pp. 1990-1999.
 
New insights into the role of PPARs.
Montagner A., Rando G., Degueurce G., Leuenberger N., Michalik L., Wahli W., 2011. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 85 (5) pp. 235-243. Peer-reviewed.
 
PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells.
Alvarez-Guardia D., Palomer X., Coll T., Serrano L., Rodríguez-Calvo R., Davidson M.M., Merlos M., El Kochairi I., Michalik L., Wahli W. et al., 2011. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, 1811 (2) pp. 59-67. Peer-reviewed.
Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism.
Garrido-Urbani S., Jemelin S., Deffert C., Carnesecchi S., Basset O., Szyndralewiez C., Heitz F., Page P., Montet X., Michalik L. et al., 2011. PloS One, 6 (2) pp. e14665.
EuroPhenome: a repository for high-throughput mouse phenotyping data.
Morgan H., Beck T., Blake A., Gates H., Adams N., Debouzy G., Leblanc S., Lengger C., Maier H., Melvin D. et al., 2010/01. Nucleic acids research, 38 (Database issue) pp. D577-85. Peer-reviewed.
 
Activation of PPAR delta Regulates Ywhae (Encoding 14-3-3 epsilon Protein), a Gene Required for Ventricular Morphogenesis
Brunelli L., Cieslik K.A., Michalik L., Wahli W., Yost H.J., 2009. pp. E15-E15 dans Basic Cardiovascular Sciences Conference 2009, Circulation Research. Peer-reviewed.
 
Nuclear factor I-C links platelet-derived growth factor and transforming growth factor beta1 signaling to skin wound healing progression.
Plasari G., Calabrese A., Dusserre Y., Gronostajski R.M., McNair A., Michalik L., Mermod N., 2009. Molecular and Cellular Biology, 29 (22) pp. 6006-6017. Peer-reviewed.
 
Parts of the bothrops moojeni snake venom activated lipid synthesis and PPARA, B, Gamma 2 in transiently transfected sz95 sebocytes
Schagen S. K., Perchuc A.-.M., Voegeli R., Imfeld D., Schreier T., Michalik L., Wahli W., Zouboulis C. C., 2009. Journal der Deutschen Dermatologischen Gesellschaft, 7 pp. 152-153. Peer-reviewed.
Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing.
Chong H.C., Tan M.J., Philippe V., Tan S.H., Tan C.K., Ku C.W., Goh Y.Y., Wahli W., Michalik L., Tan N.S., 2009. Journal of Cell Biology, 184 (6) pp. 817-831. Peer-reviewed.
Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2.
Rodríguez-Calvo R., Serrano L., Coll T., Moullan N., Sánchez R.M., Merlos M., Palomer X., Laguna J.C., Michalik L., Wahli W. et al., 2008. Diabetes, 57 (8) pp. 2149-2157. Peer-reviewed.
PPARs Mediate Lipid Signaling in Inflammation and Cancer.
Michalik L., Wahli W., 2008. PPAR Research, 2008 p. 134059. Peer-reviewed.
 
Tissue repair and cancer control through PPARs and their coregulators
Michalik L., Wahli W., 2008. pp. 409-440 dans Kumar B., O'Malley R. W. (eds.) Nuclear Receptor Coregulators in Human Diseases chap. 13, World Scientific Publishing.
 
Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior.
Michalik L., Zoete V., Krey G., Grosdidier A., Gelman L., Chodanowski P., Feige J.N., Desvergne B., Wahli W., Michielin O., 2007. Journal of Biological Chemistry, 282 (13) pp. 9666-9677. Peer-reviewed.
 
Guiding ligands to nuclear receptors.
Michalik L., Wahli W., 2007. Cell, 129 (4) pp. 649-651. Peer-reviewed.
 
Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease.
Michalik L., Wahli W., 2007. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, 1771 (8) pp. 991-998. Peer-reviewed.
 
Roles of the peroxisome proliferators-activated receptor (PPAR) alpha and beta/delta in skin wound healing
Michalik L., Wahli W., 2007., Proceedings of the Esteve Foundation Symposium 12, held between 4 and 7 October 2006, S'Agaro (Girona), Spain pp. 45-52 dans Werner S. (eds.) Molecular Biology and Pharmacology of tissue Repair, International Congress Series, Elsevier.
 
The nuclear hormone receptor peroxisome proliferator-activated receptor beta/delta potentiates cell chemotactism, polarization, and migration.
Tan N.S., Icre G., Montagner A., Bordier-ten-Heggeler B., Wahli W., Michalik L., 2007. Molecular and Cellular Biology, 27 (20) pp. 7161-7175. Peer-reviewed.
 
From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.
Feige J.N., Gelman L., Michalik L., Desvergne B., Wahli W., 2006. Progress in Lipid Research, 45 (2) pp. 120-159. Peer-reviewed.
 
Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis.
Icre G., Wahli W., Michalik L., 2006. Journal of Investigative Dermatology, 11 (1) pp. 30-35. Peer-reviewed.
 
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S. et al., 2006. Pharmacological Reviews, 58 (4) pp. 726-741. Peer-reviewed.
 
Involvement of PPAR nuclear receptors in tissue injury and wound repair.
Michalik L., Wahli W., 2006. Journal of Clinical Investigation, 116 (3) pp. 598-606. Peer-reviewed.
 
Physiological ligands of PPARs in inflammation and lipid homeostasis
Lathion C., Michalik L., Wahli W., 2006. Future Lipidology, 1 (2) pp. 191-201. Peer-reviewed.
 
PPARs and colon cancers : A curse or a cure ?
Michalik L., Wahli W., 2006. pp. 145-161 dans Bamba H., Ota S. (eds.) Recent Advances in Gastrointestinal Carcinogenesis, Transworld Research Network.
 
PPARs in fetal and early postnatal development
Rotman N., Michalik L., Desvergne B., Wahli W., 2006. pp. 33-64 dans Tanejah R. (eds.) Nuclear receptors in development chap. 2, Elsevier.
 
PPARs: lipid sensors that regulate cell differentiation processes
Varnat F., Michalik L., Desvergne B., Wahli W., 2006. pp. 117-131 dans Brigelius-Flohé R., Joost H.G. (eds.) Nutritional genomics : impact on health and disease chap. 7, Wiley-VCH.
 
Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock.
Canaple L., Rambaud J., Dkhissi-Benyahya O., Rayet B., Tan N.S., Michalik L., Delaunay F., Wahli W., Laudet V., 2006. Molecular Endocrinology, 20 (8) pp. 1715-1727. Peer-reviewed.
 
Transcriptional regulation of metabolism.
Desvergne B., Michalik L., Wahli W., 2006. Physiological Reviews, 86 (2) pp. 465-514. Peer-reviewed.
 
Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice.
Skrtic S., Carlsson L., Ljungberg A., Lindén D., Michalik L., Wahli W., Oscarsson J., 2005. Liver International, 25 (1) pp. 33-40. Peer-reviewed.
 
EMPReSS: standardised phenotype screens for functional annotation of the mouse genome
Eumorphia_Consortium, Wahli W., Delgado MB., Desvergne B., Michalik L., Bedu E., 2005. Nature Genetics, 37 (11) p. 1155. Peer-reviewed.
 
Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor beta/delta during hair follicle development.
Di-Poï N., Ng C.Y., Tan N.S., Yang Z., Hemmings B.A., Desvergne B., Michalik L., Wahli W., 2005. Molecular and Cellular Biology, 25 (5) pp. 1696-1712. Peer-reviewed.
 
Genetic- or transforming growth factor-beta 1-induced changes in epidermal peroxisome proliferator-activated receptor beta/delta expression dictate wound repair kinetics.
Tan N.S., Michalik L., Desvergne B., Wahli W., 2005. Journal of Biological Chemistry, 280 (18) pp. 18163-18170. Peer-reviewed.
 
Kinase signaling cascades that modulate peroxisome proliferator-activated receptors.
Gelman L., Michalik L., Desvergne B., Wahli W., 2005. Current Opinion in Cell Biology, 17 (2) pp. 216-222. Peer-reviewed.
 
Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes.
Tan N.S., Michalik L., Desvergne B., Wahli W., 2005. Journal of Steroid Biochemistry and Molecular Biology, 93 (2-5) pp. 99-105. Peer-reviewed.
 
Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor alpha transcriptional up-regulation of fatty acid oxidation.
Gremlich S., Nolan C., Roduit R., Burcelin R., Peyot M.L., Delghingaro-Augusto V., Desvergne B., Michalik L., Prentki M., Wahli W., 2005. Endocrinology, 146 (1) pp. 375-382. Peer-reviewed.
 
Peroxisome proliferator activated receptors
Genolet R., Michalik L., Wahli W., 2005. pp. 267-280 dans Dufour J.F., Clavien P.A., Trautwein C., Graf R. (eds.) Signaling pathways in liver diseases, Springer.
Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes.
Planavila A., Rodríguez-Calvo R., Jové M., Michalik L., Wahli W., Laguna J.C., Vázquez-Carrera M., 2005. Cardiovascular Research, 65 (4) pp. 832-841. Peer-reviewed.
 
PPARs in diseases: control mechanisms of inflammation.
Kostadinova R., Wahli W., Michalik L., 2005. Current Medicinal Chemistry, 12 (25) pp. 2995-3009. Peer-reviewed.
 
Promoter rearrangements cause species-specific hepatic regulation of the glyoxylate reductase/hydroxypyruvate reductase gene by the peroxisome proliferator-activated receptor alpha.
Genolet R., Kersten S., Braissant O., Mandard S., Tan N.S., Bucher P., Desvergne B., Michalik L., Wahli W., 2005. Journal of Biological Chemistry, 280 (25) pp. 24143-24152. Peer-reviewed.
 
Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing.
Michalik L., Feige J.N., Gelman L., Pedrazzini T., Keller H., Desvergne B., Wahli W., 2005. Molecular Endocrinology, 19 (9) pp. 2335-2348. Peer-reviewed.
 
Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins.
Di-Poï N., Desvergne B., Michalik L., Wahli W., 2005. Journal of Biological Chemistry, 280 (46) pp. 38700-38710. Peer-reviewed.
 
Altered growth in male peroxisome proliferator-activated receptor gamma (PPARgamma) heterozygous mice: involvement of PPARgamma in a negative feedback regulation of growth hormone action.
Rieusset J., Seydoux J., Anghel S.I., Escher P., Michalik L., Soon Tan N., Metzger D., Chambon P., Wahli W., Desvergne B., 2004. Molecular Endocrinology, 18 (10) pp. 2363-2377. Peer-reviewed.
 
Be fit or be sick: peroxisome proliferator-activated receptors are down the road.
Desvergne B., Michalik L., Wahli W., 2004. Molecular Endocrinology, 18 (6) pp. 1321-1332. Peer-reviewed.
 
Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator-activated receptor beta) in skin wound healing.
Tan N.S., Michalik L., Di-Poï N., Desvergne B., Wahli W., 2004. Biochemical Society Transactions, 32 (Pt 1) pp. 97-102. Peer-reviewed.
 
Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression.
Tan N.S., Michalik L., Di-Poï N., Ng C.Y., Mermod N., Roberts A.B., Desvergne B., Wahli W., 2004. EMBO Journal, 23 (21) pp. 4211-4221. Peer-reviewed.
Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis.
Di-Poï N., Michalik L., Desvergne B., Wahli W., 2004. Lipids, 39 (11) pp. 1093-1099. Peer-reviewed.
 
Impaired expression of NADH dehydrogenase subunit 1 and PPARgamma coactivator-1 in skeletal muscle of ZDF rats: restoration by troglitazone.
Jové M., Salla J., Planavila A., Cabrero A., Michalik L., Wahli W., Laguna J.C., Vázquez-Carrera M., 2004. Journal of Lipid Research, 45 (1) pp. 113-123. Peer-reviewed.
 
Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARalpha.
Sanguino E., Ramón M., Michalik L., Wahli W., Alegret M., Sánchez R.M., Vázquez-Carrera M., Laguna J.C., 2004. Biochemical Pharmacology, 67 (1) pp. 157-166. Peer-reviewed.
 
Peroxisome proliferator-activated receptor-beta as a target for wound healing drugs.
Tan N.S., Michalik L., Desvergne B., Wahli W., 2004. Expert Opinion on Therapeutic Targets, 8 (1) pp. 39-48. Peer-reviewed.
 
Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation.
Mao-Qiang M., Fowler A.J., Schmuth M., Lau P., Chang S., Brown B.E., Moser A.H., Michalik L., Desvergne B., Wahli W. et al., 2004. Journal of Investigative Dermatology, 123 (2) pp. 305-312. Peer-reviewed.
 
Peroxisome-proliferator-activated receptors and cancers: complex stories.
Michalik L., Desvergne B., Wahli W., 2004. Nature Reviews. Cancer, 4 (1) pp. 61-70. Peer-reviewed.
 
PPARs as drug targets to modulate inflammatory responses?
Genolet R., Wahli W., Michalik L., 2004. Current Drug Targets. Inflammation and Allergy, 3 (4) pp. 361-375. Peer-reviewed.
 
PPARs in health and disease : central roles in energy homeostasis and tissue repair.
Wahli W, Michalik L, Desvergne B, 2004. BIO, 11 pp. 26-31. Peer-reviewed.
 
Peroxisome proliferator-activated receptors beta/delta: emerging roles for a previously neglected third family member.
Michalik L., Desvergne B., Wahli W., 2003/04. Current opinion in lipidology, 14 (2) pp. 129-135. Peer-reviewed.
 
Peroxisome proliferator-activated receptor (PPAR)-beta as a target for wound healing drugs: what is possible?
Tan N.S., Michalik L., Desvergne B., Wahli W., 2003. American Journal of Clinical Dermatology, 4 (8) pp. 523-530.
 
Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells.
Hellemans K., Michalik L., Dittie A., Knorr A., Rombouts K., De Jong J., Heirman C., Quartier E., Schuit F., Wahli W. et al., 2003. Gastroenterology, 124 (1) pp. 184-201. Peer-reviewed.
 
Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer.
Jackson L., Wahli W., Michalik L., Watson S.A., Morris T., Anderton K., Bell D.R., Smith J.A., Hawkey C.J., Bennett A.J., 2003. Gut, 52 (9) pp. 1317-1322.
 
PPARbeta regulates vitamin A metabolism-related gene expression in hepatic stellate cells undergoing activation.
Hellemans K., Rombouts K., Quartier E., Dittié A.S., Knorr A., Michalik L., Rogiers V., Schuit F., Wahli W., Geerts A., 2003. Journal of Lipid Research, 44 (2) pp. 280-295.
 
PPARs: nuclear receptors involved in the control of inflammation
Michalik L., Tan N. S., Wahli W., Desvergne B., 2003. pp. 419-435 dans Duttaroy A.K., Spener F. (eds.) Cellular proteins and their fatty acids in health and disease chap. 24, Wiley VCH.
 
Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones.
Jalouli M., Carlsson L., Améen C., Lindén D., Ljungberg A., Michalik L., Edén S., Wahli W., Oscarsson J., 2003. Endocrinology, 144 (1) pp. 101-109.
 
The anti-apoptotic role of PPARbeta contributes to efficient skin wound healing.
Di-Poï N., Michalik L., Tan N.S., Desvergne B., Wahli W., 2003. Journal of Steroid Biochemistry and Molecular Biology, 85 (2-5) pp. 257-265.
 
A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity.
Rieusset J., Touri F., Michalik L., Escher P., Desvergne B., Niesor E., Wahli W., 2002. Molecular Endocrinology, 16 (11) pp. 2628-2644.
 
Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway.
Di-Poï N., Tan N.S., Michalik L., Wahli W., Desvergne B., 2002. Molecular Cell, 10 (4) pp. 721-733.
 
PPAR expression and function during vertebrate development.
Michalik L., Desvergne B., Dreyer C., Gavillet M., Laurini R.N., Wahli W., 2002/01. International Journal of Developmental Biology, 46 (1) pp. 105-114.
 
PPARs: transcriptional effectors of fatty acids and their derivatives.
Hihi A.K., Michalik L., Wahli W., 2002. Cellular and Molecular Life Sciences, 59 (5) pp. 790-798.
 
Sensors for metabolic control : a regulatory network of nuclear receptors
Desvergne B., Michalik L., Wahli W., 2002. pp. 283-304 dans Goffin V., Kelly P.A. (eds.) Hormone signaling chap. 14, Kluwer Academic Publishers.
 
Critical roles of PPAR beta/delta in keratinocyte response to inflammation.
Tan N.S., Michalik L., Noy N., Yasmin R., Pacot C., Heim M., Flühmann B., Desvergne B., Wahli W., 2001/12. Genes and Development, 15 (24) pp. 3263-3277.
 
Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding.
Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., Desvergne B., 2001/10. Endocrinology, 142 (10) pp. 4195-4202.
Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice.
Michalik L., Desvergne B., Tan N.S., Basu-Modak S., Escher P., Rieusset J., Peters J.M., Kaya G., Gonzalez F.J., Zakany J. et al., 2001. Journal of Cell Biology, 154 (4) pp. 799-814.
 
Les bases moléculaires de l'obésité : vers de nouvelles thérapeutiques ?
Michalik L., Desvergne B., Wahli W., 2000. Medecine Sciences, 16 (10) pp. 1030-1039. Peer-reviewed.
 
Nuclear hormone receptors and mouse skin homeostasis: implication of PPARbeta.
Michalik L., Desvergne B., Basu-Modak S., Tan N.S., Wahli W., 2000. Hormone Research, 54 (5-6) pp. 263-268.
 
Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions.
Michalik L., Wahli W., 1999/12. Current Opinion in Biotechnology, 10 (6) pp. 564-570.
 
Expression of specific tau exons in normal and tumoral pancreatic acinar cells.
Vanier M.T., Neuville P., Michalik L., Launay J.F., 1998/05. Journal of Cell Science, 111 ( Pt 10) pp. 1419-1432.
 
In situ localization with digoxigenin-labelled probes of tau-related mRNAs in the rat pancreas.
Neuville P., Vanier M.T., Michalik L., Launay J.F., 1995/08. Histochemical Journal, 27 (8) pp. 565-574.
 
Pancreatic tau related maps: biochemical and immunofluorescence analysis in a tumoral cell line.
Michalik L., Neuville P., Vanier M.T., Launay J.F., 1995/02. Molecular and Cellular Biochemistry, 143 (2) pp. 107-112.
 
Identification of a microtubule-binding domain sequence in pancreatic messenger RNAs.
Neuville P., Michalik L., Launay J.F., 1993/06. Biochimica et Biophysica Acta: Molecular Basis of Disease, 1181 (3) pp. 317-320. Peer-reviewed.
 
Biochemical and immunochemical identification of a microtubule-binding protein from bovine pancreas.
Michalik L., Neuville P., Vanier M.T., Launay J.F., 1993. Cell Motility and the Cytoskeleton, 25 (4) pp. 381-390.
 
Characterization of a 67 kDa microtubule-binding protein in the pancreas from different species
Michalik Liliane, Vanier Marie-Thérèse, Launay Jean-François, 1992/06. Biochimica et Biophysica Acta (BBA) - General Subjects, 1116 (3) pp. 269-273. Peer-reviewed.
 
Microtubule affinity chromatography: a new technique for isolating microtubule-binding proteins from rat pancreas.
Michalik L., Vanier M.T., Launay J.F., 1991. Cellular and Molecular Biology, 37 (8) pp. 805-811.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University